CAS 11021-14-0 Ginsenoside Rc molecular structure

lightbox

CAS RN: 11021-14-0

Ginsenoside Rc

Product Availability

Choose a grade to view its available package options.

8 package records8 with current stock2 grade groups

Grade In stock only

Batch No.	Package	Availability	Warehouse	Inquiry
Batchno.20260501	100mg	In stock	Shanghai	Inquiry
Batchno.20250321	10mg	In stock	Shanghai	Inquiry
Batchno.20251231	1mg	In stock	Shanghai, Wuhan	Inquiry
Batchno.20260207	250mg	In stock	Shanghai	Inquiry
Batchno.20250819	25mg	In stock	Shanghai	Inquiry
Batchno.20250325	50mg	In stock	Shanghai	Inquiry
Batchno.20250526	5mg	In stock	Shanghai	Inquiry

Batch No.	Package	Availability	Warehouse	Inquiry
Batchno.20250809	20mg	In stock	Shanghai, Chongqing	Inquiry

Product code: starshine_CAS11021-14-0
Purity/Analytical Methods: >99.0%

GET A QUOTE

11021-14-0 / (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-17-[(2S)-2-[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-6-methylhept-5-en-2-yl]-12-hydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

2-[2-[[17-[2-[6-[[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-6-methylhept-5-en-2-yl]-12-hydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol | SCHEMBL27947082 | CHEBI:91809

Standard CAS: 11021-14-0 Multi CAS: Yes

Basic Information Computed Properties Safety & Transport

Basic Information

CAS

11021-14-0

Multi CAS

Yes

Molecular Formula

C53H90O22

Molecular Weight

1079.300000

Exact Mass

1078.592374

SMILES

CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@@H](O8)CO)O)O)O)O)O)C

InChI

InChI=1S/C53H90O22/c1-23(2)10-9-14-53(8,75-47-43(67)39(63)37(61)29(72-47)22-68-45-41(65)36(60)28(21-56)69-45)24-11-16-52(7)33(24)25(57)18-31-50(5)15-13-32(49(3,4)30(50)12-17-51(31,52)6)73-48-44(40(64)35(59)27(20-55)71-48)74-46-42(66)38(62)34(58)26(19-54)70-46/h10,24-48,54-67H,9,11-22H2,1-8H3/t24-,25+,26+,27+,28-,29+,30-,31+,32-,33-,34+,35+,36-,37+,38-,39-,40-,41+,42+,43+,44+,45+,46-,47-,48-,50-,51+,52+,53-/m0/s1

InChIKey

JDCPEKQWFDWQLI-LUQKBWBOSA-N

Synonyms

Computed Properties

Structural Parameters

Heavy atom count

Fraction Csp3

0.96

Rotatable bonds

H-bond acceptors

H-bond donors

Molar refractivity

260.21

TPSA

357.06

LogP / Solubility

WLOGP

-1.56

MLOGP

-1.27

XLogP3

0.9

Consensus LogP

-0.64

Log S (ESOL)

-4.49

Class (ESOL)

Slightly soluble

Log S (Ali)

-7.28

Class (Ali)

Insoluble

Log S (SILICOS-IT)

-7.3

Class (SILICOS-IT)

Insoluble

ADME

GI absorption

Low

BBB permeant

P-gp substrate

Yes

CYP1A2 inhibitor

CYP2C19 inhibitor

CYP2C9 inhibitor

CYP2D6 inhibitor

CYP3A4 inhibitor

Log Kp (skin permeation)

-10.41

Drug-likeness / Medicinal Chemistry

Lipinski

Ghose

Veber

Egan

Muegge

Bioavailability score

0.17

Brenk alerts

Leadlikeness

Synthetic Accessibility

Safety & Transport

Pictogram(s)

Irritant

Signal

Warning

GHS Hazard Statements

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] H312 (95.5%): Harmful in contact with skin [Warning Acute toxicity, dermal] H332 (95.5%): Harmful if inhaled [Warning Acute toxicity, inhalation]

Precautionary Statement Codes

P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501